[Training in electrocardiographic recording].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C Abe.
Explore the source record for details and available documents.
Influenza virus A/Kumamoto haemagglutinin was found to induce type I, III, and IV hypersensitivity in mice. MRL/Mp-I pr/lpr (MRL/l) mice are known to be lower responders to, and poor inducers of, interleukin-2 (IL-2). Recombinant IL-2 was found to augment the type III reaction in BALB/c mice and to suppress the reaction in MRL/I mice in vivo. Cyclophosphamide 100 mg/kg had a selective suppressive effect on the suppressor T cells responsible for type IV reaction, and subsequently the delayed type hypersensitivity (DTH) was augmented. Higher doses of cyclophosphamide suppressed both suppressor and effector T cells in DTH, and subsequently the DTH was suppressed markedly. This experimental model system employing viral haemagglutinin may provide a new screening method for the development of immunomodulators.
Explore the source record for details and available documents.
Isolation of Propionibacterium acnes from biopsied lymph nodes of sarcoidosis patients and from the lymph nodes or other tissues of non-sarcoidosis patients was carried out, carefully avoiding contamination by skin-resident P. acnes. Out of 40 sarcoidosis lymph nodes examined, 31 nodes (77.5%) showed a positive culture of P. acnes, while 38 of 180 (21.1%) non-sarcoidosis tissues revealed positive results, the difference being significant (p less than 0.001). Among non-sarcoidosis tissues, the intra-thoracic lymph nodes demonstrated a positive culture in low percentages, while intra-abdominal lymph nodes indicated no positive culture. The possible role of this microorganism in the etiology of sarcoidosis is discussed.
The response of the mean circulatory pressure (MCP), an index of the tone of the systemic capacitance vessels, to the infusion of an alpha-adrenergic receptor stimulant (phenylephrine) and a beta-adrenergic receptor stimulant (isoproterenol) was studied in anesthetized, open-chest dogs. Provided that the blood volume (particularly, extra volume) remains constant, an increase in the MCP indicates an increase in the tone of the capacitance vessels ("venoconstriction") and a decrease in the MCP indicates a decrease in the tone of the capacitance vessels ("venodilation"). It was almost definitely concluded that the stimulation of the alpha-adrenergic receptor led to the increased tone of the systemic capacitance vessels and the stimulation of the beta-adrenergic receptor did not decrease the tone of the systemic capacitance vessels in anesthetized, open-chest dogs, but the stimulation of the beta-adrenergic receptor decreased the tone of the systemic capacitance vessels, when the tone had been previously elevated by angiotensin-II.
The production of spleen- and thymus-rosette forming cells (RFC) in BALB/c mice 4 days after immunization with 5 X 10(8) sheep red blood cells (SRBC) was inhibited by traxanox at doses of 10-30 mg/kg, p.o. This agent (100 mg/kg, p.o.) suppressed the 19S hemagglutinin titer and elevated the 7S hemagglutinin titer. The transfer of spleen-RFC of thymus-RFC into syngeneic recipient mice 4 days after immunization with SRBC increased the production of spleen hemolytic plaque forming cells (HPFC). This increase was abolished by the transfer of spleen-RFC obtained from mice treated with traxanox (30 mg/kg, p.o.), but not by the transfer of spleen-RFC treated with anti-Lyt 2.2 antiserum and complement. The viability of the spleen-RFC in mice treated with traxanox was decreased by treatment with anti-Lyt 2.2 antiserum and complement. Traxanox (3-30 mg/kg, p.o) significantly increased the inhibition of HPFC, spleen-RFC and thymus-RFC production by Concanavalin A at a dose of 50 micrograms/mouse. This agent (3-30 mg/kg, p.o) inhibited the production of HPFC, spleen-RFC and thymus-RFC in mice 4 days after the secondary immunization. These results suggest that traxanox may inhibit antibody production via the induction of Lyt 2.2 positive cells (suppressor T cells).
A multicenter double-blind study was carried out in patients with rheumatoid arthritis (RA) by comparing treatment with a novel immunomodulator, lobenzarit, disodium 4-chloro-2, 2'-iminodibenzoate, with an inert placebo. Both groups of patients received 75 mg/day of indomethacin as a basal regimen during the study period of 16 weeks. Group 1 (115 patients) received 240 mg/day lobenzarit, 80 mg TID, and Group 2 (115 patients) received placebo TID orally. A statistically significant improvement was noted in the number of swollen joints and in the Lansbury index at Weeks 12 and 16 in Group 1 as compared to Group 2. Overall clinical effectiveness was significantly higher in Group 1 (63%) than in Group 2 (43%). Incidence of side effects was 38% in Group 1 and 22% in Group 2. The most frequent side effect in both groups was gastrointestinal upset. Our data confirm that lobenzarit is a useful agent in the treatment of patients with RA.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A study to elucidate the immunopharmacological mechanisms of carboxyphenyl chloroanthranilic acid (CCA) was carried out, employing as a parameter the rosette formation of mouse spleen and thymus cells with red blood cells of sheep. The immunopharmacological properties of CCA and levamisole (LMS) were compared. In C57BL/6 mice, the immune response was either suppressed or enhanced by LMS, whereas CCA caused a suppression of rosette formation. Both drugs enhanced response in adult thymectomized C57BL/6 mice. LMS induced Thy-1 positive rosette-forming cells after adult thymectomy in C57BL/6 mice, whereas CCA did not. CCA was significantly effective in restoring the impaired immune response in C57BL/6 mice pretreated with immunosuppressants. The effect of LMS or CCA on the immune response varied among six different mouse strains (C57BL/6, BALB/c, C3H/He, DBA/2, (NZB X NZW) F1 and BXSB). The results suggest that both drugs have immunomodulation or immunonormalization properties.
Both C57BL/6 and BALB/c mice were immunized intravenously with lipopolysaccharide (LPS, 10 micrograms/mouse) on day 0, and hemolytic plaque forming cells (HPFC) in the spleen were assayed on day 4. Traxanox given orally at a dose of 30 mg/kg augmented the HPFC production to LPS in both mice. This agent (3-30 mg/kg) restored significantly the suppressed HPFC production to LPS in the BALB/c mice pretreated with carrageenan (0.03 mg/mouse), but did not restore it in the BALB/c mice pretreated with cyclophosphamide (25 mg/kg). The transfer of spleen adherent cells of the mice immunized with LPS and treated with traxanox to the syngeneic mice resulted in a significant increase in the HPFC production to LPS. The HPFC production to trinitrophenylated polyvinylpyrrolidone, a T cell-independent antigen was not affected by the treatment with traxanox or carrageenan. These results suggest that traxanox has a capacity to augment the immune response by affecting macrophage function.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Japanese patients with rheumatoid arthritis (RA) were observed to have a statistical association with HLA-DR4, MT3. Strong association between the clinical severity of RA and HLA was also observed. Male patients had a stronger association with HLA than female patients. Males are more resistant to RA than females. This suggested that the threshold of liability for RA is higher in males than in females. Japanese patients with RA with systemic vasculitis were negative for HLA-Bw44 and had antilymphocytotoxic autoantibody, indicating that RA with systemic vasculitis is different in etiology from RA without systemic vasculitis.